

REMARKS

Currently Claims 1-23 are pending. Applicants have cancelled claim 23 and added new claim 24, support for which can be found at page 45, lines 13-17, among other places. Claims 1, 3-7, 9, 12, 13, 15-17, and 22 have been amended to place them in form appropriate to US practice, to reduce the filing fee by removing multiple dependencies, and/or to correct typographical errors.


The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:


J. Michael Strickland
Attorney for Applicants
Reg. No. 47,115

Date: January 25, 2005
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988

ABSTRACT

A medicament dispenser device for use in the delivery of a combination medicament product is disclosed. The device includes a first medicament container for containing a first medicament component; first release means for releasing the contents of the first medicament container; at least one further medicament container for containing at least one further medicament component; at least one further release means for releasing the contents of each the at least one further medicament container; and mixing means for promoting the mixing of the released contents of the first and at least one further medicament container. The first medicament component is kept separate from the at least one further medicament component until the point of release thereof for delivery in combination.